Roivant rises as arthritis drug shows early promise

Roivant Sciences

20/05/2026 15:37

** Shares of drug developer Roivant Sciences ROIV.O rise 14.3% to $32.23

** Co says early-stage data showed its experimental drug,  IMVT-1402, reduced symptoms in patients with difficult-to-treat rheumatoid arthritis (D2T RA), an autoimmune condition that causes joint pain and swelling

** Says among 165 evaluable patients, 72.7% of patients showed a ≥ 20% improvement from baseline in tender joint count and swollen joint count, while 54.5% and 35.8% showed higher responses

** Cantor Fitzgerald says the responses "are meaningfully better than any benchmark in this highly refractory rheumatoid arthritis setting"

** Leerink Partners says "We thus see the potential for IMVT-1402 to become a blockbuster in D2T RA given its differentiated mechanism and compelling efficacy in patients who have failed multiple prior therapies"

** ROIV expects to provide further updates on the program in the second half of 2026

** Including session's move, ROIV up 47.8% YTD

 (Reporting by Kunal Das in Bengaluru)

 ((Kunal.Das2@thomsonreuters.com;))